An Open-Label, Dose Finding, International Phase 2 Study With Once Monthly Subcutaneous VRS-317 in Adult Growth Hormone Deficiency (GHD)

Trial Profile

An Open-Label, Dose Finding, International Phase 2 Study With Once Monthly Subcutaneous VRS-317 in Adult Growth Hormone Deficiency (GHD)

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Somavaratan (Primary)
  • Indications Growth disorders; Somatotropin deficiency
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms VITAL
  • Sponsors Versartis
  • Most Recent Events

    • 27 Jul 2017 According to a Versartis media release, data will be presented at the 10th Annual International Joint Meeting of Pediatric Endocrinology (IMPE) Sep 2017.
    • 10 Jun 2017 Biomarkers information updated
    • 04 Apr 2017 Results of an ad hoc analysis on preliminary data assessing correlation between baseline IGF-I, dose, and response presented at The 99th Annual Meeting of the Endocrine Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top